Roche’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD)

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice